Mr. Daniell became Executive Vice President, European Commercial in November 2017.
From December 2016 to November 2017, he served as President and CEO, Teva Europe Generics.
From 2015 to 2016, he served as Chief Integration Officer, leading the integration of the Actavis Generics business into Teva and also served as Chief Operating Officer of International Markets.
From 2011 to 2015 he served as Cluster General Manager, United Kingdom and Ireland.
Mr. Daniell received a B.Sc. degree in chemistry from the University of Auckland, New Zealand.